Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.47 |
| ▸ | CNR1 | P21554 | 8/20 | 0.46 |
| ▸ | CNR2 | P34972 | 8/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5516011 | 0.90 | CNR1 (0.52) | CNR1CNR2BCL2L1 | |
| SCHEMBL14472350 | 0.88 | CNR2 (0.44) | CNR1CNR2P2RX3 | |
| SCHEMBL5524996 | 0.88 | CNR2 (0.44) | CNR1CNR2P2RX3 | |
| SCHEMBL2746246 | 0.88 | CNR2 (0.44) | CNR1CNR2P2RX3 | |
| SCHEMBL2746618 | 0.88 | CNR1 (0.49) | CNR1CNR2P2RX3 | |
| SCHEMBL2745331 | 0.86 | KMT2A (0.51) | TAS1R3TAS1R1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL5519479 | 0.86 | KMT2A (0.51) | TAS1R3TAS1R1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL5519444 | 0.86 | KMT2A (0.51) | TAS1R3TAS1R1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL5521147 | 0.85 | CNR2 (0.60) | CNR1CNR2 | |
| SCHEMBL2747934 | 0.85 | CNR2 (0.60) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806342-B1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | TAS1R3 609/4885TAS1R1 637/4885CNR1 2/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | TAS1R3 422/4885TAS1R1 540/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.